Tonze New Energy Technology (002759.SZ) issued a profit warning, expecting a net loss of 1.25 billion to 1.5 billion for the fiscal year of 2024, a change from profit to loss compared to the previous year.
Tianji Group (002759.SZ) released its performance forecast for the year 2024, expecting full-year attributable to shareholders of the listed company...
Tonze New Energy Technology (002759.SZ) announced its performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company of 12.5 billion to 15 billion yuan for the whole year, turning from profit to loss compared to the previous year.
Due to the fierce competition in the market of its main product, lithium hexafluorophosphate, there has been a significant decrease in prices. As a major enterprise in the lithium hexafluorophosphate industry, the company has a large production and sales scale, and all three subsidiaries that mainly produce lithium hexafluorophosphate products recorded losses, with a total loss exceeding 3 billion yuan and a net loss of approximately 2.5 billion yuan.
The corresponding industry of the company's main product lithium hexafluorophosphate is still in a downturn, with temporary excess production capacity in the industry, forecasting a decrease in future profitability. The goodwill of the corresponding assets was tested to be impaired, with an estimated impairment amount of around 1 billion yuan. After this impairment provision, the remaining carrying value of goodwill for lithium hexafluorophosphate assets is approximately 4.4 billion yuan.
The company's wholly-owned subsidiary, Changshu Xintehuacheng Chemical Co., Ltd. (hereinafter referred to as "Xintehuacheng"), is expected to not meet its performance commitments for 2024 due to factors such as production stoppage for technical upgrades and price declines in major products during the first half of 2024. The goodwill of the corresponding assets was tested to be impaired, with an estimated impairment amount of around 0.5 billion yuan. After this impairment provision, the remaining carrying value of goodwill for Xintehuacheng assets is approximately 2.8 billion yuan.
Related Articles

CHAODA MODERN (00682) Announces Annual Results, Loss Attributable to Shareholders of 15.884 Million Yuan, Up 8.5% Year-on-Year
Guangdong Zhongsheng Pharmaceutical (002317.SZ) obtained the drug registration certificate for Emedastine Difumarate Eye Drops.

ZYLOXTB (02190) repurchased 53,000 shares for HK$1,138,300 on September 29.
CHAODA MODERN (00682) Announces Annual Results, Loss Attributable to Shareholders of 15.884 Million Yuan, Up 8.5% Year-on-Year

Guangdong Zhongsheng Pharmaceutical (002317.SZ) obtained the drug registration certificate for Emedastine Difumarate Eye Drops.
ZYLOXTB (02190) repurchased 53,000 shares for HK$1,138,300 on September 29.






